A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain
In the European Union, the high-concentration capsaicin patch is licensed for the management of neuropathic pain conditions in nondiabetic patients, including postherpetic neuralgia (PHN) and HIV-associated distal sensory polyneuropathy (HIV-DSP). However, in the USA, the Food and Drug Administratio...
Main Authors: | Ganesan Baranidharan, Sangeeta Das, Arun Bhaskar |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2013-09-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285613496862 |
Similar Items
-
Profile of the capsaicin 8% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability
by: Laklouk M, et al.
Published: (2016-09-01) -
Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain
by: Peppin JF, et al.
Published: (2011-11-01) -
Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study
by: Colette Mankowski, et al.
Published: (2017-04-01) -
Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland.
by: Colette Mankowski, et al.
Published: (2016-01-01) -
Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain
by: Huygen F, et al.
Published: (2020-10-01)